Table 3.
Clinical Characteristics of Patients With Secondary Prevention Indication by Presence or Absence of Shock
| No Appropriate Shock | Appropriate Shock | P Value | |
|---|---|---|---|
| N=1619 | N=310 | ||
| Demographics | |||
| Male, n (%) | 1291 (79.7) | 269 (86.8) | 0.004 |
| Age, mean±SD | 65.40±12.69 | 65.82±12.00 | 0.589 |
| Cardiomyopathy details | |||
| Ischemic, n (%) | 1437 (88.8) | 275 (88.7) | … |
| Ischemic+previous revascularization, n (%) | 1163 (71.8) | 214 (69.0) | 0.491 |
| Previous heart failure, n (%) | 366 (22.6) | 73 (23.5) | 0.717 |
| Device details | |||
| Cardiac resynchronizator‐defibrillator, n (%) | 146 (9.0) | 32 (10.3) | 0.82 |
| Dual‐chamber ICD, n (%) | 700 (43.2) | 131 (42.3) | … |
| Single‐chamber ICD, n (%) | 771 (47.6) | 147 (47.4) | … |
| Medical comorbidities | |||
| Atrial fibrillation, n (%) | 510 (31.5) | 99 (31.9) | 0.88 |
| Diabetes mellitus, n (%) | 419 (25.9) | 53 (17.1) | <0.001 |
| Current cigarette smoking, n (%) | 271 (16.7) | 54 (17.4) | 0.769 |
| Hypertension, n (%) | 1018 (62.9) | 191 (61.6) | 0.673 |
| Stroke or transient ischemic attack, n (%) | 71 (4.4) | 16 (5.2) | 0.546 |
| Peripheral vascular disease, n (%) | 172 (10.6) | 47 (15.2) | 0.021 |
| Any cancer, n (%) | 133 (7.4) | 33 (9.4) | 0.195 |
| COPD, n (%) | 173 (10.7) | 46 (14.8) | 0.035 |
| Clinical variables | |||
| Reported NYHA class | |||
| III or IV, n (%) | 237 (14.6) | 46 (14.8) | … |
| Systolic blood pressure, mean±SD | 124.60±19.98 | 124.70±20.66 | 0.94 |
| QRS duration in ms, mean±SD | 121.91±33.63 | 125.37±30.59 | 0.095 |
| Testing | |||
| Serum creatinine level, median (IQR) | 95.00 (79.00–117.00) | 95.00 (81.00–117.00) | 0.763 |
| Hb <110 g/L, n (%) | 360 (22.2) | 62 (20.0) | 0.004 |
| LVEF | |||
| LVEF ≤20, n (%) | 162 (10.0) | 39 (12.6) | 0.174 |
| LVEF: 21 to 30, n (%) | 400 (24.7) | 71 (22.9) | 0.498 |
| LVEF: >30, n (%) | 913 (56.4) | 166 (53.5) | 0.355 |
| Medications | |||
| β‐Adrenoreceptor antagonist, n (%) | 1353 (83.6) | 263 (84.8) | 0.579 |
| ACEI, n (%) | 1059 (65.4) | 214 (69.0) | 0.218 |
| ARB, n (%) | 218 (13.5) | 35 (11.3) | 0.299 |
| Spironolactone, n (%) | 245 (15.1) | 42 (13.5) | 0.473 |
| Loop diuretics, n (%) | 631 (39.0) | 122 (39.4) | 0.9 |
| Digoxin, n (%) | 198 (12.2) | 40 (12.9) | 0.741 |
| Amiodarone, n (%) | 574 (35.5) | 122 (39.4) | 0.19 |
| Statin, n (%) | 1163 (71.8) | 223 (71.9) | 0.971 |
| Aspirin, n (%) | 1160 (71.6) | 216 (69.7) | 0.482 |
| Clopidogrel, n (%) | 494 (30.5) | 92 (29.7) | 0.77 |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; Hb, hemoglobin; ICD, implantable cardioverter defibrillator; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.